{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.48","value":"27.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Duration of response (DoR) is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression (i.e. date of progression free survival event or censoring - date of first response + 1). The end of response should coincide with the date of progression or death from any cause used for the progression free survival endpoint. The time of the initial response is defined as the latest of the dates contributing towards the first visit that was Complete response or Partial response that was subsequently confirmed.\n\nPer the protocol, the safety run-in treatment arms were combined and analyzed regardless of chemotherapy received for consistency with the randomized component.","dispersionType":"Standard Deviation","groups":[{"description":"Includes all participants in both Safety Run-In treatment arms: AZD9291 + Carboplatin + Pemetrexed and AZD9291 + Cisplatin + Pemetrexed","id":"OG000","title":"Overall Safety Run-In Participants"}],"paramType":"MEAN","populationDescription":"Participants from the Safety Analysis Set, which includes all participants in the Safety Run-In Treatment Arms who received at least 1 dose of study treatment (osimertinib, cisplatin, carboplatin, or pemetrexed), that had a confirmed response.","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Duration of Response (DoR) (Safety Run-In Treatment Arms Only)","type":"SECONDARY","unitOfMeasure":"Months"}